March 3, 2006

Genta has announced results from a randomized, double-blind Phase II trial that showed Ganite (gallium nitrate injection) was highly effective when compared with Aredia (pamidronate disodium) in hospitalized patients with cancer-related hypercalcemia. This condition, in which blood calcium levels may rise to immediately life- threatening levels, is the most common metabolic complication in patients with advanced cancer.

In this trial, 64 patients who had been hospitalized with hypercalcemia were randomly assigned to receive Ganite or one of two doses of Aredia plus placebo for four days. The primary endpoint of the study was to describe the proportion of patients who subsequently achieved a normal blood calcium level (normocalcemia). In this critically ill population, 22 of 32 patients treated with Ganite achieved normocalcemia compared with 18 of 32 patients treated with Aredia. Patients with severe hypercalcemia did not respond better to 90 mg of pamidronate than to 60 mg of pamidronate, or compared with the response to Ganite in patients with severe hypercalcemia.